查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1584097

达菲市场，按剂型、药物类型、适应症、配销通路、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Tamiflu Market, By Dosage Form, By Drug Type, By Indication, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 322 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023年达菲市场规模为192,032万美元，2024年至2032年复合年增长率为3.40%。

达菲市场-市场动态

全球季节性流感盛行率不断上升，COVID-19 大流行期间需求增加，推动市场需求

达菲（磷酸奥司他韦）是一种抗病毒药物，适用于治疗两週及以上、出现流感症状不到两天的急性、无併发症的甲型和乙型流感以及猪流感(H1N1) 。它有胶囊和口服混悬剂两种形式。达菲（磷酸奥司他韦）的市场预计将在预测期内增长，原因是全球季节性流感患病率上升，以及由于其相对轻微的副作用，在 COVID-19 大流行期间需求增加。此外，许多製药公司推出磷酸奥司他韦仿製药预计将进一步推动市场扩张。由于达菲用于治疗甲型、乙型流感和猪流感，全球流感病例的增加预计将提振市场。例如，根据世界卫生组织 2021 年 11 月的报告，2020 年全球有 300 至 500 万例严重流感病例。

达菲市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032）每年将以 3.40% 左右的复合年增长率成长

根据药物类型细分，预计仿製药将在 2023 年显示最大的市场份额

按剂型细分，2023年胶囊剂为主导类型

按地区划分，北美是 2023 年的主要收入来源

达菲市场-細項分析：

全球达菲市场根据剂型、药物类型、适应症、配销通路和地区进行细分。

市场依药物类型分为两类：品牌药物和仿製药。预计仿製药细分市场将在预测期内主导市场，这主要是由于对治疗季节性流感的磷酸奥司他韦的高需求推动的。达菲的仿製药提供了更具成本效益的解决方案，使更广泛的患者和医疗保健系统更容易获得它们。这种负担能力，加上与品牌药物相当的功效，导致人们对仿製药的强烈偏好，特别是在医疗保健模式对成本敏感的地区。此外，由于许多製药公司在达菲专利到期后推出了仿製药替代品，市场竞争加剧，进一步压低了价格并提高了药物的供应量。

市场依剂型分为两类：胶囊剂和混悬剂。由于胶囊市场广泛偏好治疗流感，预计在整个预测期内将引领市场。胶囊方便、易于给药，通常受到患者和医疗保健提供者等的青睐，用于治疗无併发症的流感病例。此外，与悬浮液相比，胶囊具有更高的稳定性和更长的保质期，使其更适合储存和分配。另一方面，口服混悬液通常适用于无法吞嚥胶囊的患者，例如幼儿或患有特定疾病的个人。虽然它在确保这些人群的可及性方面发挥着重要作用，但与胶囊剂相比，口服混悬剂的需求仍然较低，从而加强了后者的市场主导地位。

达菲市场-地理洞察

预计北美地区将在预测期内主导达菲市场，主要是由于其庞大的市场份额以及为即将到来的流感季节准备的达菲库存增加。例如，2022 年 12 月 21 日，美国政府宣布，美国卫生与公众服务部 (HHS) 与战略准备和响应管理局 (ASPR) 合作，正在储存额外的达菲供应，以满足不断增长的需求2022 年流感季节期间。这是透过国家战略储备（SNS）来实现的。政府将与 ASPR 区域小组合作，评估 SNS 分发达菲的请求，确保各州、地区和部落获得必要的支持，同时为未来大流行流感爆发做好准备。

达菲市场-竞争格局：

达菲市场的公司实施了一系列策略来提高其竞争地位并增加市场占有率。其中包括旨在教育医疗保健提供者和公众有关流感预防和治疗的强有力的营销活动。公司还优先考虑与政府和卫生组织建立伙伴关係，以获得在流感季节或大流行期间储存抗病毒药物的合约。研究和开发工作也很重要，投资重点是创造下一代抗病毒疗法以对抗新出现的流感病毒株。此外，定价策略旨在与医疗保健系统预算保持一致，同时确保有需要的患者能够获得广泛的服务。

最新进展：

2022年12月，美国生技公司Genentech, Inc.宣布达菲（磷酸奥司他韦）可在美国全国销售，使药品能够运送到全国的药局。

目录

第一章：达菲市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 达菲市场片段（按剂型）
    • 按药物类型分類的达菲市场片段
    • 达菲市场片段（按适应症）
    • 按配销通路分類的达菲市场片段
    • 按国家/地区分類的达菲市场摘要
    • 按地区分類的达菲市场片段
  • 竞争洞察

第 3 章：达菲主要市场趋势

  • 达菲市场驱动因素
    • 市场驱动因素的影响分析
  • 达菲市场限制
    • 市场限制影响分析
  • 达菲市场机会
  • 达菲市场未来趋势

第 4 章：达菲产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：达菲市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：达菲市场格局

  • 2023 年达菲市占率分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：达菲市场 - 按剂型

  • 概述
    • 按剂型分類的细分市场份额分析
    • 胶囊
    • 暂停

第 8 章：达菲市场 - 按药物类型

  • 概述
    • 按药物类型分類的细分市场份额分析
    • 品牌化
    • 通用选项

第 9 章：达菲市场 - 依适应症分类

  • 概述
    • 按指标分類的细分市场占有率分析
    • 甲型流感
    • 乙型流感
    • 猪流感（H1N1 甲型流感）

第 10 章：达菲市场 - 按配销通路

  • 概述
    • 按配销通路分類的细分市场份额分析
    • 医院药房
    • 零售药局
    • 网路药局

第 11 章：达菲市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 达菲北美主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模与预测（按剂型）
    • 北美市场规模和预测（按药物类型）
    • 北美市场规模和预测（按指标）
    • 北美市场规模和预测（按配销通路）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 达菲欧洲主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模与预测（按剂型）
    • 欧洲市场规模和预测（按药物类型）
    • 欧洲市场规模与预测（按指标）
    • 欧洲市场规模和预测（按配销通路）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 达菲亚太地区主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模与预测（按剂型）
    • 亚太地区市场规模和预测（按药物类型）
    • 亚太地区市场规模与预测（依指标）
    • 亚太地区市场规模和预测（按配销通路）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲达菲主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按剂型）
    • 拉丁美洲市场规模与预测（按药物类型）
    • 拉丁美洲市场规模与预测（按指标）
    • 拉丁美洲市场规模和预测（按配销通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 达菲在中东和非洲的主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按剂型）
    • 中东和非洲市场规模及预测（按药物类型）
    • 中东和非洲市场规模及预测（依指标）
    • 中东和非洲市场规模及预测（按配销通路）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 12 章：主要供应商分析 - 达菲产业

  • 竞争仪表板
  • 公司简介
    • F. Hoffmann-La Roche Ltd.
    • NATCO Pharma Limited
    • Teva Pharmaceutical Industries Ltd
    • LUPIN Limited
    • Amneal pharmaceuticals LLC
    • Zydus Cadila
    • Sun Pharmaceutical Industries Ltd.
    • Alembic Pharmaceuticals Limited
    • Mylan NV
    • Hetero Group
    • Others

第 13 章：360 度分析师视角

第 14 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4087

REPORT HIGHLIGHT

Tamiflu Market size was valued at USD 1,920.32 Million in 2023, expanding at a CAGR of 3.40% from 2024 to 2032.

Tamiflu, also known as oseltamivir, is an antiviral medication commonly used to treat and prevent influenza infections. It works by inhibiting neuraminidase enzyme, which the virus needs to spread within the respiratory system. Tamiflu is most effective in reducing flu symptoms' duration and severity when taken within the first 48 hours of symptom onset. It can also be prescribed as a preventive measure for individuals at high risk of complications from the flu. Due to its effectiveness, Tamiflu is critical in public health efforts during flu outbreaks and pandemics.

Tamiflu Market- Market Dynamics

Increasing prevalence of seasonal influenza worldwide and increased demand during the COVID-19 pandemic to propel market demand

Tamiflu (oseltamivir phosphate) is an antiviral medication indicated for the treatment of acute, uncomplicated influenza A and B, as well as swine flu (H1N1), in patients aged two weeks and older who have had flu symptoms for less than two days. It is available in both capsule and oral suspension forms. The market for Tamiflu (oseltamivir phosphate) is expected to grow over the forecast period, driven by the rising prevalence of seasonal influenza worldwide and increased demand during the COVID-19 pandemic, due to its relatively mild side effects. Additionally, the launch of generic versions of oseltamivir phosphate by many pharmaceutical companies is anticipated to further fuel market expansion. As Tamiflu is indicated for treating influenza A, B, and swine flu, the global rise in influenza cases is expected to boost the market. For instance, according to a November 2021 report by the World Health Organization, in 2020, there were 3 to 5 million cases of severe influenza illness globally.

Tamiflu Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 3.40% over the forecast period (2024-2032)

Based on Drug Type segmentation, generic was predicted to show maximum market share in the year 2023

Based on Dosage Form segmentation, capsules was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Tamiflu Market- Segmentation Analysis:

The Global Tamiflu Market is segmented on the basis of Dosage Form, Drug Type, Indication, Distribution Channel, and Region.

The market is divided into two categories based on Drug Type: branded and generic options. The generic segment is anticipated to dominate the market during the forecast period, largely driven by the high demand for oseltamivir phosphate in treating seasonal influenza. Generic versions of Tamiflu offer a more cost-effective solution, making them more accessible to a broader range of patients and healthcare systems. This affordability, coupled with comparable efficacy to branded drugs, contributes to the strong preference for generics, especially in regions with cost-sensitive healthcare models. Additionally, as many pharmaceutical companies have launched generic alternatives following the expiration of Tamiflu's patent, the market has seen increased competition, further driving down prices and boosting the availability of the drug.

The market is divided into two categories based on Dosage Form: capsules and suspension. The capsule segment is expected to lead the market throughout the forecast period due to its widespread preference for treating influenza. Capsules are convenient, easy to administer, and typically preferred by patients and healthcare providers alike for treating uncomplicated influenza cases. Furthermore, capsules offer more stability and have a longer shelf life compared to suspensions, making them more practical for stockpiling and distribution. Oral suspension, on the other hand, is generally reserved for patients who are unable to swallow capsules, such as young children or individuals with specific medical conditions. While it serves an important role in ensuring accessibility for these populations, the demand for oral suspension remains lower compared to capsules, reinforcing the latter's market dominance.

Tamiflu Market- Geographical Insights

The North America region is expected to dominate the Tamiflu market during the forecast period, primarily due to its significant market share and the increased stockpiling of Tamiflu in preparation for upcoming influenza seasons. For example, on December 21, 2022, the U.S. government announced that the U.S. Department of Health and Human Services (HHS), in collaboration with the Administration for Strategic Preparedness and Response (ASPR), is storing additional supplies of Tamiflu to meet rising demand during the 2022 flu season. This was achieved through the Strategic National Stockpile (SNS). The government, working with ASPR Regional Teams, will assess requests for Tamiflu distribution from the SNS, ensuring that states, territories, and tribes receive necessary support while maintaining preparedness for future pandemic influenza outbreaks.

Tamiflu Market- Competitive Landscape:

Companies in the Tamiflu market implement a range of strategies to improve their competitive position and increase market share. These include robust marketing campaigns aimed at educating healthcare providers and the public about flu prevention and treatment. Firms also prioritize partnerships with governments and health organizations to secure contracts for stockpiling antiviral medications during flu seasons or pandemics. Research and development efforts are important as well, with investments focused on creating next-generation antiviral therapies to combat emerging influenza strains. Further, pricing strategies are designed to align with healthcare system budgets while ensuring broad access for patients in need.

Recent Developments:

In December 2022, Genentech, Inc., U.S. biotechnology corporation, announced that Tamiflu (oseltamivir phosphate) was available for distribution across the U.S., enabling drug shipments to pharmacies nationwide.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL TAMIFLU MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • F. Hoffmann-La Roche Ltd.
  • NATCO Pharma Limited
  • Teva Pharmaceutical Industries Ltd
  • LUPIN Limited
  • Amneal pharmaceuticals LLC
  • Zydus Cadila
  • Sun Pharmaceutical Industries Ltd.
  • Alembic Pharmaceuticals Limited
  • Mylan N.V.
  • Hetero Group
  • Others

GLOBAL TAMIFLU MARKET, BY DOSAGE FORM- MARKET ANALYSIS, 2019 - 2032

  • Capsules
  • Suspension

GLOBAL TAMIFLU MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Branded
  • Generic options

GLOBAL TAMIFLU MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Influenza A
  • Influenza B
  • Swine Flu (H1N1 Influenza A)

GLOBAL TAMIFLU MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

GLOBAL TAMIFLU MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Tamiflu Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Tamiflu Market Snippet by Dosage Form
    • 2.1.2. Tamiflu Market Snippet by Drug Type
    • 2.1.3. Tamiflu Market Snippet by Indication
    • 2.1.4. Tamiflu Market Snippet by Distribution Channel
    • 2.1.5. Tamiflu Market Snippet by Country
    • 2.1.6. Tamiflu Market Snippet by Region
  • 2.2. Competitive Insights

3. Tamiflu Key Market Trends

  • 3.1. Tamiflu Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Tamiflu Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Tamiflu Market Opportunities
  • 3.4. Tamiflu Market Future Trends

4. Tamiflu Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Tamiflu Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Tamiflu Market Landscape

  • 6.1. Tamiflu Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Tamiflu Market - By Dosage Form

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Dosage Form, 2023 & 2032 (%)
    • 7.1.2. Capsules
    • 7.1.3. Suspension

8. Tamiflu Market - By Drug Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
    • 8.1.2. Branded
    • 8.1.3. Generic options

9. Tamiflu Market - By Indication

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Indication, 2023 & 2032 (%)
    • 9.1.2. Influenza A
    • 9.1.3. Influenza B
    • 9.1.4. Swine Flu (H1N1 Influenza A)

10. Tamiflu Market - By Distribution Channel

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 10.1.2. Hospital pharmacies
    • 10.1.3. Retail pharmacies
    • 10.1.4. Online pharmacies

11. Tamiflu Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Tamiflu Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Tamiflu Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Tamiflu Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Tamiflu Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Tamiflu Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Tamiflu Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. F. Hoffmann-La Roche Ltd.
    • 12.2.2. NATCO Pharma Limited
    • 12.2.3. Teva Pharmaceutical Industries Ltd
    • 12.2.4. LUPIN Limited
    • 12.2.5. Amneal pharmaceuticals LLC
    • 12.2.6. Zydus Cadila
    • 12.2.7. Sun Pharmaceutical Industries Ltd.
    • 12.2.8. Alembic Pharmaceuticals Limited
    • 12.2.9. Mylan N.V.
    • 12.2.10. Hetero Group
    • 12.2.11. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us